NCT00126022

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects With Recent Onset Atrial Fibrillation

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate the ability of tedisamil to convert atrial fibrillation or flutter into normal sinus rhythm (NSR) in female patients.

Conditions

• Atrial Fibrillation
• Atrial Flutter

Interventions

Type	Name	Description
DRUG	Tedisamil sesquifumarate

Timeline

• Start date: 2004-12-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-08-02
• Last updated: 2015-01-16

Locations

81 sites across 13 countries: United States, Argentina, Czechia, Germany, Israel, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, South Africa, Ukraine, United Kingdom